Synthetic tetrapeptide
Epitalon
A tetrapeptide promoted for sleep and longevity despite identity transfer problems and no established insomnia or lifespan outcome evidence.
Also known as Epithalon · AEDG · epitalon acetate
01 · Evidence profile
One molecule, four evidence questions
FDA found no studies establishing insomnia outcomes for the nominated epitalon substances and route.
Melatonin and cell-line findings are indirect and do not establish patient benefit.
Human product, route, exposure, impurity, and long-term safety data are inadequate.
Evidence often mixes epitalon, epitalon acetate, and non-identical pineal preparations.
02 · Identity
What it is
Epitalon is the tetrapeptide Ala-Glu-Asp-Gly. It is frequently discussed alongside epithalamin, a pineal preparation, but those are not the same intervention.
03 · Product identity
The molecule is not the finished product.
Epitalon, epitalon acetate, and older pineal extracts such as epithalamin are not automatically interchangeable evidence objects.
None identified in the United States.
- No FDA-approved indication
04 · Evidence snapshot
What the evidence can and cannot say
Laboratory work has reported telomere-related effects in human cell lines. FDA's current review found melatonin-related information but no clinical insomnia studies using the nominated substances by the proposed route.
Cell-line telomere changes do not establish slower aging, longer life, cancer prevention, or improved health in people. Evidence from epithalamin cannot be silently reassigned to epitalon.
05 · Claim check
Three claims under the lens
“Epitalon changes telomere biology in human cell lines.”
A 2025 laboratory study reported telomere-length effects in cultured human cell lines.
- Evidence basis
- Preclinical evidence
- Scope
- Cultured cell lines, not health outcomes in treated people.
“Epitalon is proven to treat insomnia.”
FDA did not identify clinical insomnia studies of the nominated epitalon substances by the proposed route.
- Evidence basis
- No reliable human outcome evidence
- Scope
- Adults with insomnia assessed using clinical sleep outcomes.
“Epitalon has been proven to extend human lifespan.”
The evidence does not provide reliable product-specific randomized lifespan outcomes for epitalon.
- Evidence basis
- No reliable human outcome evidence
- Scope
- Human lifespan and healthspan outcomes attributable to epitalon.
06 · Safety boundary
Before this becomes personal
Longevity claims demand long-duration human outcomes, not only mechanisms. This guide provides no injectable, sleep-treatment, or anti-aging regimen.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed 2026-07-23. This status is not personal clearance to compete.07 · Sources
Check the primary record
08 · Provenance
Review history
Initial brief reflects FDA's July 2026 insomnia-focused evidence review before final agency action.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.